Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5

Tejal A. Patel; Bhuvanesh Dave; Angel A. Rodriguez; Jenny C. Chang; Edith A. Perez; Gerardo Colon-Otero

doi:10.1186/s13058-014-0468-9

Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5

Tejal A. Patel, Bhuvanesh Dave, Angel A. Rodriguez, Jenny C. Chang, Edith A. Perez, Gerardo Colon-Otero

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).

Original language	English (US)
Article number	468
Journal	Breast Cancer Research
Volume	16
Issue number	1
DOIs	https://doi.org/10.1186/s13058-014-0468-9
State	Published - Nov 6 2014

ASJC Scopus subject areas

Oncology
Cancer Research

Divisions

Medical Oncology

Access to Document

10.1186/s13058-014-0468-9

Cite this

@article{1688b225a25d4275add2f94707b6c6e2,

title = "Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5",

abstract = "After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).",

author = "Patel, \{Tejal A.\} and Bhuvanesh Dave and Rodriguez, \{Angel A.\} and Chang, \{Jenny C.\} and Perez, \{Edith A.\} and Gerardo Colon-Otero",

note = "Publisher Copyright: {\textcopyright} 2014 Patel et al.",

year = "2014",

month = nov,

day = "6",

doi = "10.1186/s13058-014-0468-9",

language = "English (US)",

volume = "16",

journal = "Breast Cancer Research",

issn = "1465-5411",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Erratum

T2 - Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5

AU - Patel, Tejal A.

AU - Dave, Bhuvanesh

AU - Rodriguez, Angel A.

AU - Chang, Jenny C.

AU - Perez, Edith A.

AU - Colon-Otero, Gerardo

PY - 2014/11/6

Y1 - 2014/11/6

N2 - After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).

AB - After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).

UR - https://www.scopus.com/pages/publications/84920766511

UR - https://www.scopus.com/inward/citedby.url?scp=84920766511&partnerID=8YFLogxK

U2 - 10.1186/s13058-014-0468-9

DO - 10.1186/s13058-014-0468-9

M3 - Comment/debate

AN - SCOPUS:84920766511

SN - 1465-5411

VL - 16

JO - Breast Cancer Research

JF - Breast Cancer Research

IS - 1

M1 - 468

ER -

Erratum: Dual HER2 blockade: Preclinical and clinical data [Breast Cancer Research, (2014)]. DOI: 10.1186/s13058-014-0419-5

Abstract

ASJC Scopus subject areas

Divisions

Access to Document

Other files and links

Fingerprint

Cite this